Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
Innate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
Innate Pharma Reports Full Year 2023 Financial Results and Business Update
Innate Pharma Announces Conference Call for Full Year 2023 Financial Results
Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501
Innate Pharma Announces Its Participation to Upcoming Investor Conference
Number of Shares and Voting Rights of Innate Pharma as of January 1, 2024